1/1
FLUORESCE: A pilot randomized clinical trial of fluoxetine for vision recovery after acute ischemic stroke
dataset
posted on 2021-04-27, 13:10 authored by Colleen SchneiderColleen Schneider, Emily Prentiss, Ania Busza, Zoe Williams, Bradford MahonBradford Mahon, Bogachan SahinBackground and purpose: Post-stroke homonymous hemianopia is disabling and complete spontaneous recovery is rare. In this randomized, double-blind, placebo-controlled pilot clinical trial, we tested whether fluoxetine enhances vision recovery after stroke.
Methods: We randomized 17 consecutive adults 1:1 to 90 days of fluoxetine 20 mg daily vs. placebo within 10 days of an ischemic stroke causing homonymous hemianopia. The primary endpoint was percent improvement in 24-2 Humphrey perimetry at six months. Twelve participants completed the study.
Results: Intention-to-treat analysis of the primary endpoint, percent improvement in perimetric mean deviation, showed a non-significant benefit of fluoxetine (64.4%, n=5) over placebo (26.0%, n=7, 95% confidence interval (CI)=(-2.13,∞), p=0.06). The original blind field completely recovered in 60% receiving fluoxetine and 14% receiving placebo (odds ratio=7.22, 95%CI=(0.50,∞)).
Conclusions: These results suggest a trend in favor of fluoxetine and should be followed up with a multi-center trial.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02737930
Funding
Cortical organization of action knowledge before and after brain surgery
National Institute of Neurological Disorders and Stroke
Find out more...Neurovascular and Neuroplastic Contributions to Visual Recovery After Stroke
National Eye Institute
Find out more...Neurorehabilitation and Restorative Neuroscience Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Find out more...Access to parietal action representations after stroke lesions in visual cortex
National Eye Institute
Find out more...Experimental Therapeutics in Neurological Disease
National Institute of Neurological Disorders and Stroke
Find out more...